跳至主要内容
临床试验/DRKS00015060
DRKS00015060进行中(未招募)不适用

Pre-screening for sensitivity to investigational anti-cancer drugs in patients with cancer

Oncology Venture ApS0 个研究点目标入组 13 人开始时间: 2018年7月10日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
13

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • i. Histological or cytological documented locally advanced or metastatic solid tumor relapsed on 1 or more different prior therapies
  • ii. Age = 18 years
  • iii. Written informed consent
  • iv. Life expectancy = 6 months
  • v. ECOG Performance status = 1
  • vi. FFPE tumor tissue available

排除标准

  • i. Other primary malignancy within the last 5 years prior to enrolment, except for adequately treated squamous cell carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
  • ii. Evidence of any other disease or psychological dysfunction giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect patients understanding of the information, compliance with study routines, or place the patient at high risk from treatment related complications.

研究者

发起方
Oncology Venture ApS

相似试验